Bronchiectasis
Methodology & AI Transparency ⓘ
Bronchiectasis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Asthma, COPD & Respiratory Disease diagnostic criteria (J47.9), workup for Bronchiectasis integrates high-resolution chest imaging in Bronchiectasis (J47.9: when indicated) with evidence-graded therapy tailored to Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)) response.
- 2 Real-world patient consensus: Mapped to Asthma, COPD & Respiratory Disease under ICD-10-CM J47.9 for Bronchiectasis clinical workups.
- 3 Typical cash cost range: Workup highlights for Bronchiectasis (J47.9): high-resolution chest imaging in Bronchiectasis (J47.9: when indicated).
- 4 Top reported side effects / signs: Longitudinal Bronchiectasis monitoring tracks Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)) toward 96% – 100% (J47.9).
Ask our AI Specialists anything about Bronchiectasis
What Is Bronchiectasis?
Under Asthma, COPD & Respiratory Disease diagnostic criteria (J47.9), workup for Bronchiectasis integrates high-resolution chest imaging in Bronchiectasis (J47.9: when indicated) with evidence-graded therapy tailored to Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Bronchiectasis (J47.9) center on mucus goblet-cell hyperplasia [Bronchiectasis J47.9]. targeted lungs & asthma interventions aim to normalize Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)).
Common Symptoms & Clinical Signs
- • Presentation of Bronchiectasis (J47.9): prolonged recovery from in Bronchiectasis (J47.9: viral respiratory infections)
- • Secondary Bronchiectasis clinical sign: declining stair-climbing stamina in Bronchiectasis (J47.9: or frequent rescue)
- • Symptom flares in Bronchiectasis correlating with Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)) deviation outside 96% – 100% (J47.9)
- • Functional lungs & asthma impact requiring high-resolution chest imaging in Bronchiectasis (J47.9: when indicated) evaluation (J47.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bronchiectasis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J47.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Bronchiectasis (J47.9: (SpO2)) | 96% – 100% (J47.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Bronchiectasis J47.9] | < 150 cells/uL (phenotyping marker) (J47.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Bronchiectasis (J47.9: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J47.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bronchiectasis
Treatment selection for Bronchiectasis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bronchiectasis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated: What a 377-Participant Study Found Aeruginosa have heterogeneous microbiota and inflammatory profiles, influencing antibiotic treatment responses in bronchiectasis. American journal of respiratory and critical care medicine • 2025-08-15 • Phase III Randomized Trial | N = 377 | 93/100 | PMID 40664229 ↗ |
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine Analysis of Brensocatib in Adult and No identified covariates were clinically relevant. CPT: pharmacometrics & systems pharmacology • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42712175 ↗ |
| What the Latest Evidence Really Says About Heart and blood vessel outcomes in patients with COPD-OSA overlap However, it is worth noting that the findings are limited by the considerable heterogeneity of the studies, all of which were observational and retrospective in nature. Sleep medicine reviews • 2022-06-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 35413500 ↗ |
| New Insights on Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with: What a 224-Participant Study Found Concurrent erlotinib with WBRT didn't improve iPFS and excessive CF detriment either in the intent-to-treat (ITT) population or in EGFR-mutant patients compared with WBRT-alone, suggesting that while safe for patients already... Neuro-oncology • 2021-06-01 • Phase III Randomized Trial | N = 224 | 82/100 | PMID 33331923 ↗ |
Bronchiectasis Patient Community & “People Like Me” Threads
Filter Bronchiectasis community threads and patient logs by age, biological sex, dosage, and treatment duration.